EXCLUSIVE LICENSE AGREEMENT by and between INNOVATION PHARMACEUTICALS INC. and ALFASIGMA S.p.A. Dated as of July 18, 2019Exclusive License Agreement • July 22nd, 2019 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 18, 2019 (the “Effective Date”), by and between INNOVATION PHARMACEUTICALS INC., a Nevada corporation with a principal place of business at 100 Cummings Center, Suit 151B, Beverly, Massachusetts (hereinafter referred to as “IPI”), and ALFASIGMA S.p.A. an Italian corporation with a principal place of business at Via Ragazzi del ’99 n.5, 40133 Bologna (Italy) (hereinafter referred to as “ALFASIGMA”). IPI and ALFASIGMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
